Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's disease.
ZEPHYR / SCIENCE PHOTO LIBRARY
By Allison DeAngelis
May 4, 2026
Biotech Startups and Venture Capital Reporter
Allison DeAngelis
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
Lyora Therapeutics launches with $2.5M in pre-seed funding to revive stalled eye gene therapy programs from Editas and Biogen,…
Lys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in Neurology
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
